PacBio
Company Snapshot
Company Overview
Pacific Biosciences (PacBio) designs, develops, and manufactures sequencing systems. SMRT sequencing technology provides single-molecule real-time detection of biological processes. The company markets RS II and Sequel Systems. It also markets consumable products, including sealed and packaged SMRT cell reagent kits (template, binding, and sequencing kits) for running its RS II and Sequel sequencing instruments.
The Sequel System, the company’s main platform, is a nucleic acid sequencing platform based on SMRT technology. PacBio has been actively adding enhancements to its Sequel system, including new multiplexing tools. The Sequel system has high throughput, is scalable, and has a low upfront capital investment, thus appealing to cost-sensitive customers.
The SMRT sequencing technology has several advantages over other NGS technologies. SMRT eliminates amplification bias and produces the least G.C. (guanine-cytosine content) bias. It also enables large-scale study of methylation and epigenetics.
Financial Highlights (FY 2025)
This information is available for BCC Research members only.
PacBio In News
Company's Business Segments
- Product : Instruments and Consumables
- Service and Other Revenue : Product Maintenance Agreements
Applications/End User Industries
- Gene Therapy
- Human Genomics
- Microbial Genomics
- Plant+Animal Genomics
- Cancer Genomics
- Biotechnology
- Life Sciences